IFNG and myeloid sarcoma: The fourth cluster (n=27) included 25 controls and 2 MS patients sorted according to higher levels of SARS-CoV-2 IgG (more than 270 AU/mL) and SARS-CoV-2 IFN-γ below 2895 mlU/mL.